Gold bars to be exempt from tariffs, White House clarifies
Investing.com - Stifel lowered its price target on Crinetics (NASDAQ:CRNX) to $58.00 from $60.00 on Friday, while maintaining a Buy rating on the stock following the company’s second-quarter 2025 report. According to InvestingPro data, analyst targets for CRNX range from $36 to $97, with a strong consensus recommendation of 1.5 (Buy).
The firm views Crinetics as well-positioned in the rare endocrinology space, with a diversified pipeline and sufficient capital as it approaches commercialization. The company’s strong financial position is reflected in its healthy current ratio of 22.5 and minimal debt-to-equity ratio of 0.04, according to InvestingPro data. Stifel noted that the September 2025 PDUFA date for paltusotine in acromegaly remains on track.
Launch preparation activities for paltusotine continue to advance, with Stifel highlighting the drug’s differentiated profile as an oral, once-daily treatment with rapid titration compared to injectable alternatives, which could drive significant adoption.
Crinetics plans to initiate Phase 3 pivotal trials for atumelnant in congenital adrenal hyperplasia (CAH) for both adults and pediatric patients in the second half of 2025. These trials will aim to demonstrate A4 normalization and glucocorticoid physiologic-replacement.
The company’s pipeline also includes CRN09682, a non-peptide drug-conjugate entering Phase 1/2 trials for neuroendocrine tumors and solid tumors, along with CRN12755 and CRN10329, which are currently in IND-enabling studies.
In other recent news, Crinetics Pharmaceuticals disclosed its Q2 2025 financial results, which showed mixed outcomes. The company reported an earnings per share (EPS) of -1.23, falling short of the anticipated -1.1. However, Crinetics Pharmaceuticals surpassed revenue expectations, bringing in $1 million compared to the forecasted $750,110. These recent developments have captured the attention of investors and analysts alike. The earnings report has sparked discussions, particularly due to the discrepancy between the EPS and revenue figures. While the revenue performance was stronger than expected, the EPS miss has raised some concerns. Analysts continue to monitor the company closely for further developments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.